Source comparison
Tesamorelin + Ipamorelin Blend Half Life: Pharmacokinetic Comparison
The table below summarizes the pharmacokinetic profile, clearance pathways, and optimal dosing windows for each peptide in the blend. And why understanding both profiles is essential for research protocol design. Ipamorelin 26–120 minutes (dose-dependent) 15–3
This comparison does not assign a generated winner or score.
- The table below summarizes the pharmacokinetic profile, clearance pathways, and optimal dosing windows for each peptide in the blend. And why understanding both profiles is essential for research protocol design.
- Ipamorelin
- 26–120 minutes (dose-dependent)
- 15–30 minutes post-subcutaneous injection
- Renal filtration (molecular weight <1000 Da); enzymatic degradation via DPP-4 and neutral endopeptidase
- 90–120 minutes (growth hormone pulse duration)
- Fasted state, 30–60 minutes pre-sleep or immediately upon waking; avoid high endogenous ghrelin periods
- Short half-life demands precise timing and fresh reconstitution; degraded peptide loses receptor selectivity
- Tesamorelin
- 26–38 minutes
- 20–40 minutes post-subcutaneous injection
- Enzymatic cleavage at peptide bonds; receptor-mediated endocytosis; renal clearance of fragments
- 8–12 hours (via sustained IGF-1 elevation and GHRH receptor signaling)
- Fasted state, 30–45 minutes pre-sleep; avoid periods of elevated somatostatin (post-meal, hyperglycemia)
- Plasma clearance is rapid, but biological activity persists through downstream signaling. Half-life and effect duration are not equivalent
- Blended Protocol
- Overlapping kinetics: ipamorelin Cmax at 15–30 min, tesamorelin at 20–40 min
- Combined Tmax window: 20–35 minutes
- Dual pathways: immediate renal filtration (ipamorelin) + enzymatic degradation and receptor internalization (tesamorelin)
- Acute pulse (90–120 min) + sustained IGF-1 elevation (8–12 hours)
- Single daily dose 30–45 minutes pre-sleep, fasted; or split-dose protocol (ipamorelin AM fasted, blend PM pre-sleep)
- Synergistic kinetics require synchronized dosing. Staggered administration negates the amplification effect